邓艳红，二级教授、主任医师、博士生导师，国家自然科学杰出青年基金获得者。中山大学附属第六医院副院长、肿瘤科学科带头人、药物临床试验机构（GCP）主任。牵头开展的FOWARC、OPTICAL和PICC等一系列临床和转化研究，4次获得ASCO口头报告。主持开展了20余项高质量临床试验，为中国结直肠癌人群寻得了最佳治疗方案，并在临床得到广泛应用。以通讯作者（含共同）在Cancer Cell、J Clin Oncol、Lancet Gastroenterology & Hepatology等国际高水平学术期刊发表论文70余篇，多项研究成果和方案被国内外指南推荐。主持多项国家重点研发计划课题、国家自然科学基金、广东省自然科学基金等。获得国家高层次人才，广东省重大人才工程青年拔尖人才，广东省医学杰出青年人才，2016年国家科技进步二等奖（第五），2018年广东省科技进步一等奖（第四），2021年国家教育部科学技术进步一等奖（第三），2023年中国抗癌协会科技奖一等奖（第四），第六届中国女医师协会五洲女子科技奖、2023年广东省五一劳动奖章等。

代表成果
1.    Zhang J#, Chi P#, Shi L#, Cui L, Gao J, Li W, Wei H, Cheng L, Huang Z, Cai G, Zhao R, Huang Z, Zhou H, Wei Y, Zhang H, Zheng J, Huang Y, Cai Y, Zhou Z, Kang L, Huang M, Wu X, Peng J, Ren D, Lan P, Wang J, Deng Y*. Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years. J Clin Oncol. 2025 Feb 20;43(6):633-640. IF:42.1
2.    Hu H, Zhang J, Li Y, Wang X, Wang Z, Wang H, Kang L, Liu P, Lan P, Wu X, Zhen Y, Pei H, Huang Z, Zhang H, Chen W, Zeng Y, Lai J, Wei H, Huang X, Chen J, Chen J, Tao K, Xu Q, Peng X, Liang J, Cai G, Ding K, Ding Z, Hu M, Zhang W, Tang B, Hong C, Cao J, Huang Z, Cao W, Li F, Wang X, Wang C, Huang Y, Zhao Y, Cai Y, Ling J, Xie X, Wu Z, Shi L, Ling L, Liu H, Wang J, Huang M, Deng Y*. OPTICAL study group. Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial. J Clin Oncol. 2024 Apr 2:JCO2301889. IF:42.1
3.    Li J, Hu H,Qin G, Bai F, Wu X, Ke H, Zhang J, Xie Y, Wu Z, Fu Y, Zheng H, Gong L, Xie Z, Deng Y*. Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair– Deficient Colorectal Cancer. Clin Cancer Res. 2024 Jan 17;30(2):368-378. IF: 9.99
4.    Li J, Wu C, Hu H, Qin G, Wu X, Bai F, Zhang J, Cai Y, Huang Y, Wang C, Yang J, Luan Y, Jiang Z, Ling J, Wu Z, Chen Y, Xie Z, Deng Y*. Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer. Cancer Cell. 2023 Jun 12;41(6):1152-1169.e7. IF: 48.79
5.    Hu H#, Kang L#, Zhang J#, Wu Z#, Wang H, Huang M, Lan P, Wu X, Wang C, Cao W, Hu J, Huang Y, Huang L, Wang H, Shi L, Cai Y, Shen C, Ling J, Xie X, Cai Y, He X, Dou R, Zhou J, Ma T, Zhang X, Luo S, Deng W, Ling L, Liu H, Deng Y*. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, noncomparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol.  Jan 2022. 1(7)38-48. IF 30.9